CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath

Stock Information for Tempest Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tempest Therapeutics Inc.

Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Strong Earnings and Biotech Resilience Define the Midweek Momentum
CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025
Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights
Talphera Announces the Appointment of Joe Todisco to Board of Directors
CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance
CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.